271 related articles for article (PubMed ID: 8891576)
1. Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: comparison to other dopamine receptor agonists.
Piercey MF; Hoffmann WE; Smith MW; Hyslop DK
Eur J Pharmacol; 1996 Sep; 312(1):35-44. PubMed ID: 8891576
[TBL] [Abstract][Full Text] [Related]
2. Excitation of type II anterior caudate neurons by stimulation of dopamine D3 receptors.
Piercey MF; Hyslop DK; Hoffmann WE
Brain Res; 1997 Jul; 762(1-2):19-28. PubMed ID: 9262154
[TBL] [Abstract][Full Text] [Related]
3. Dopamine receptor agonist potencies for inhibition of cell firing correlate with dopamine D3 receptor binding affinities.
Kreiss DS; Bergstrom DA; Gonzalez AM; Huang KX; Sibley DR; Walters JR
Eur J Pharmacol; 1995 Apr; 277(2-3):209-14. PubMed ID: 7493610
[TBL] [Abstract][Full Text] [Related]
4. Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease.
Piercey MF
Clin Neuropharmacol; 1998; 21(3):141-51. PubMed ID: 9617505
[TBL] [Abstract][Full Text] [Related]
5. Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors.
Mierau J; Schneider FJ; Ensinger HA; Chio CL; Lajiness ME; Huff RM
Eur J Pharmacol; 1995 Jun; 290(1):29-36. PubMed ID: 7664822
[TBL] [Abstract][Full Text] [Related]
6. D1 dopamine receptor activity of anti-parkinsonian drugs.
Fici GJ; Wu H; VonVoigtlander PF; Sethy VH
Life Sci; 1997; 60(18):1597-603. PubMed ID: 9126882
[TBL] [Abstract][Full Text] [Related]
7. The behavioural effects of pramipexole, a novel dopamine receptor agonist.
Maj J; Rogóz Z; Skuza G; Kołodziejczyk K
Eur J Pharmacol; 1997 Apr; 324(1):31-7. PubMed ID: 9137910
[TBL] [Abstract][Full Text] [Related]
8. Antiparkinson concentrations of pramipexole and PHNO occupy dopamine D2(high) and D3(high) receptors.
Seeman P; Ko F; Willeit M; McCormick P; Ginovart N
Synapse; 2005 Nov; 58(2):122-8. PubMed ID: 16088951
[TBL] [Abstract][Full Text] [Related]
9. Behavioral and neurochemical data suggest functional differences between dopamine D2 and D3 receptors.
Svensson K; Carlsson A; Huff RM; Kling-Petersen T; Waters N
Eur J Pharmacol; 1994 Oct; 263(3):235-43. PubMed ID: 7843260
[TBL] [Abstract][Full Text] [Related]
10. Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behavior.
Collins GT; Witkin JM; Newman AH; Svensson KA; Grundt P; Cao J; Woods JH
J Pharmacol Exp Ther; 2005 Jul; 314(1):310-9. PubMed ID: 15833897
[TBL] [Abstract][Full Text] [Related]
11. Pramipexole--a new dopamine agonist for the treatment of Parkinson's disease.
Bennett JP; Piercey MF
J Neurol Sci; 1999 Feb; 163(1):25-31. PubMed ID: 10223406
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the efficacy of pramipexole for treating levodopa-induced dyskinesia in patients with Parkinson's disease.
Utsumi H; Okuma Y; Kano O; Suzuki Y; Iijima M; Tomimitsu H; Hashida H; Kubo S; Suzuki M; Nanri K; Matsumura M; Murakami H; Hattori N;
Intern Med; 2013; 52(3):325-32. PubMed ID: 23370739
[TBL] [Abstract][Full Text] [Related]
13. Differential induction of adenylyl cyclase supersensitivity by antiparkinson drugs acting as agonists at dopamine D1/D2/D3 receptors vs D2/D3 receptors only: parallel observations from co-transfected human and native cerebral receptors.
Aloisi G; Silvano E; Rossi M; Millan MJ; Maggio R
Neuropharmacology; 2011; 60(2-3):439-45. PubMed ID: 21035472
[TBL] [Abstract][Full Text] [Related]
14. The discriminative stimulus effects of dopamine D2- and D3-preferring agonists in rats.
Koffarnus MN; Greedy B; Husbands SM; Grundt P; Newman AH; Woods JH
Psychopharmacology (Berl); 2009 Apr; 203(2):317-27. PubMed ID: 18807248
[TBL] [Abstract][Full Text] [Related]
15. Pre-clinical studies of pramipexole: clinical relevance.
Hubble JP
Eur J Neurol; 2000 May; 7 Suppl 1():15-20. PubMed ID: 11054154
[TBL] [Abstract][Full Text] [Related]
16. Effects of the D3 preferring dopamine agonist pramipexole on sleep and waking, locomotor activity and striatal dopamine release in rats.
Lagos P; Scorza C; Monti JM; Jantos H; Reyes-Parada M; Silveira R; Ponzoni A
Eur Neuropsychopharmacol; 1998 May; 8(2):113-20. PubMed ID: 9619689
[TBL] [Abstract][Full Text] [Related]
17. Agonistic actions of pergolide on firing activity of dopamine neurons in substantia nigra compacta area.
Zhang XX; Jin GZ; Wei YF
Zhongguo Yao Li Xue Bao; 1995 Sep; 16(5):423-7. PubMed ID: 8701759
[TBL] [Abstract][Full Text] [Related]
18. Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D1, D2 and D3 receptors.
Perachon S; Schwartz JC; Sokoloff P
Eur J Pharmacol; 1999 Feb; 366(2-3):293-300. PubMed ID: 10082211
[TBL] [Abstract][Full Text] [Related]
19. The activity of pramipexole in the mouse forced swim test is mediated by D2 rather than D3 receptors.
Siuciak JA; Fujiwara RA
Psychopharmacology (Berl); 2004 Sep; 175(2):163-9. PubMed ID: 14985923
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Parkinson's disease should begin with a dopamine agonist.
Montastruc JL; Rascol O; Senard JM
Mov Disord; 1999 Sep; 14(5):725-30. PubMed ID: 10495032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
